New Consumer Report, January 11 news, recently, a new horizontal clinical study showed that compared with smokers, the risk of BAT's nicotine products Velo's risk of smoking -related diseases has been significantly reduced; in addition A big data study based on the Japanese medical data center shows that after the introduction of smokeless products (HTP and other heating products such as HTP), the number of hospitalizations of chronic obstructive pulmonary disease and heart disease has decreased significantly, which means that smokeless products are on the public to the public Health has potential positive influence.

Nicotine (NPS) is a smoke -free product, which has potentially positive effects in reducing the tuber hazard strategy. A new horizontal clinical study published on Biomarkers shows that the BAT nicotine product Velo is lower than that of cigarettes, and the level of harmful substances is lower (poisonous based on WHO).

The research invites subjects 15 to 55 years old from Denmark and Sweden, divided into four groups of participants who have used Velo for more than 6 months, current smokers, former smokers, and people who never smoke. , Analyze the level of the ultimate biomarker in the urine and blood. The results show that compared with smokers, consumers related to Velo products are lower level, while biomarkers related to risks such as lung cancer, cardiovascular disease and general inflammation are significantly different. It can reduce the potential health risks generated by smoking.

BAT Science Director David O'Reilly said in an interview, "These results further prove that supporting Velo can make important contributions to reducing the harm of tobacco. The longer these nicotine substitutes are listed, the more real data we can collect. These data will strengthen our belief in reducing the hazards of tobacco and building a "better tomorrow '"

Another study published on "Frontiers in Public Health" also believes that new tobacco -free tobacco products have a significant impact on reducing cardiopulmonary disease. The research surveyed the hospitalization rate of two severe health status in Japan from 2013-2020: chronic obstructive pulmonary disease (COPD) and heart disease. As a result, it was found that after the establishment of heating tobacco products (HTP) in the market, the number of hospitalizations of these diseases was obviously obvious decline.

The above figures are chronic obstructive pulmonary disease (COPD) and cardiac disease hospitalization rates in Japan from 2013 to 2020. The hospitalization rates of the two diseases after the establishment of the HTP market in 2017 were declining. Choosing January 2017 as the starting point of intervention was because the Japanese HTP market share had reached 7%at that time, and then accelerated to 25%at the end of 2019. Therefore, this is judged to be established in the market. The real data source used is the Japanese Medical Data Center (JMDC) insurance claim database, which contains accumulated receipts and diagnostic procedure combinations (DPC) data of about 7.3 million patients as of April 2020.

Dr. Moira Gilchrist, Vice President of PMI Fimo International, commented, "The study of this peer review is very encouraging because it highlights real evidence, indicating that our heating tobacco products may have a positive impact on public health."

References

David Azzopardi，Linsey E. Haswell，Justin Frosina,et al. Assessment Of Biomarkers Of Exposure And Potential Harm, And Physiological And Subjective Health Measures In Exclusive Users Of Nicotine Pouches And Current, Former And Never Smokers. Biomarkers,2022

Vander Plas，Antunes，Romero-Kauss,et al. Ischemic Heart Disease and Chronic Obstructive Pulmonary Disease Hospitalizations in Japan Before and After the Introduction of a Heated Tobacco Product. Frontiers in Public Health,2022